Press Release
Evoke Pharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at the Lotte New York Palace Hotel in New York City.
Mr. Gonyer will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 18th Annual Rodman & Renshaw Global Investment Conference
Date: Monday, September 12, 2016
Time: 2:10-2:35pm ET
Location: Holmes I; Lotte New York Palace Hotel in New York City
A copy of the corporate presentation will be posted to the Company's website prior to the conference.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. Visit www.EvokePharma.com for more information.
Investor Contact: The Ruth Group David Burke O: 646-536-7009 C: 917-618-2651 dburke@theruthgroup.com